Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Section 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Curr Pain Headache Rep. 2020 Sep 29;24(11):68. doi: 10.1007/s11916-020-00902-7.
This review provides an update on chronic cluster headache (CH) focusing on clinical features, pathophysiology, and management as well as comparisons between Eastern and Western populations.
Chronic CH in Eastern populations was relatively rare, compared to that in Western populations. Lacrimation and/or conjunctival injection is the most frequently reported cranial autonomic symptom, and visual aura is predominant in chronic CH patients. Neuroimaging evidence in both ethnic groups suggests that CH pathophysiology involves the hypothalamus and pain-modulatory areas, with dynamic alternations between CH episodes. Recent evidence indicates that midbrain dopaminergic systems may participate in CH chronicity. Noteworthy advances have emerged in neuromodulatory therapies for chronic CH, but treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies has been unsuccessful. Recent evidence shows divergence of chronic CH between Eastern and Western populations. Neuromodulatory therapies but not CGRP inhibition is effective in this intractable patient group.
本文就慢性丛集性头痛(CH)的临床特征、病理生理学和治疗进行了综述,并对东西方人群进行了比较。
与西方人群相比,东方人群的慢性 CH 相对少见。流泪和/或结膜充血是最常报告的颅自主症状,而视觉先兆在慢性 CH 患者中占主导地位。两个种族的神经影像学证据均表明 CH 的病理生理学涉及下丘脑和痛觉调节区,在 CH 发作之间存在动态交替。最近的证据表明,中脑多巴胺能系统可能参与 CH 的慢性过程。在慢性 CH 的神经调节治疗方面取得了显著进展,但降钙素基因相关肽(CGRP)单克隆抗体治疗失败。最近的证据表明,CH 在东西方人群中存在差异。神经调节治疗而非 CGRP 抑制对这一难治性患者群体有效。